November 2014
Issue
US Supplement
European
Supplement
The Next Chapter in TEVAR
An introduction by Nicky James, Vice President and Global Business Unit Leader of Aortic Intervention at Cook Medical, and a discussion with Tilo Kölbel, MD, PhD, from Hamburg, Germany, about his vast experience with TEVAR and the challenges we face today.
Why Do TEVAR Grafts Fail?
The Cleveland Clinic experience in treating serious complications that can occur after TEVAR.
By Eric E. Roselli, MD
A New Option for a Wider Range of Anatomies
Early EU experience with the new Zenith Alpha Thoracic Endovascular Graft.
By Piergiorgio Cao, MD, FRCS, and Ciro Ferrer, MD
The Benefits of Utilizing a Low-Profile TAA Device
Factors that make the low-profile Zenith Alpha Thoracic aortic aneurysm device more useful than a standard abdominal aortic aneurysm device.
By Michael C. Moon, MD
Treating Trauma
Case studies and early experience with the Zenith Alpha Thoracic Endovascular Graft for treatment of blunt aortic injuries.
By Benjamin W. Starnes, MD, FACS
advertisement
Top 5 Articles From November 2014
Penetrating Aortic Ulcer and Intramural Hematoma
An update on how to differentiate and manage two potentially devastating diagnoses.
By Foeke Nauta, MD; Arnoud Kamman, MD; and Santi Trimarchi, MD, PhD
Coding Changes for 2015
Reviewing the changes and additions to endovascular coding effective January 1.
By Katharine L. Krol, MD, FSIR, FACR
Total Endovascular Repair of the Aortic Arch
An overview of branched arch devices on the horizon.
By Stéphan Haulon, MD, PhD; Jonathan Sobocinski, MD, PhD; Rafaelle Spear, MD; Jarin Kratzberg, PhD; Blayne Roeder, PhD; Richard Azzaoui, MD; and Blandine Maurel, MD, PhD
Minimally Invasive Sutureless Anastomosis of an AV Hemodialysis Graft
An overview of the InterGraft™ Vascular Anastomotic Connector System and a case report from the first-in-human study.
By Adrian Ebner, MD; John Ross, MD; and Alexander Yevzlin, MD
Arch Debranching Is Best
Without sufficient long-term data on the use of chimney or branched grafts, arch debranching is the preferred treatment modality.
By Stephen W. K. Cheng, MD
Top 5 from CIToday's Current Issue
Massive Thromboembolism, PFO, and Acute Limb Ischemia
By Moderator: Mohamad Alkhouli, MD
Panelists: Yashu Dhamija, MD; Abdul Moiz Hafiz, MD; Ankur Kalra, MD, FACP, FACC, FSCAI; and Anmar Kanaa’N, MD
Meeting the Challenge…
By Azeem Latib, MD
Compensation and Production Trends for Interventionalists
A look at MedAxiom’s annual report reflecting the continued evolution of the field in terms of physician demand and compensation agreements.
